Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. We focus on Combination Products of two or more drugs with complementary and synergistic effects and optimized delivery profiles, providing high clinical value and shorter regulatory pathways (US 505b2 approach). The company develops products in two therapeutic areas with great unmet needs - Parkinson's disease (PD) and Cancer.All of Pharma Two B candidates are known drugs. The company efforts are primarily devoted to pharmacologically characterizing and optimizing synergistic combinations with improved therapeutic effect. In addition, Pharma Two B provides, based on our vast experience in the field of drug delivery and controlled release, optimized formulations which enhance the pharmacological activity and provide additional value to the new products IP.